(of a substance) released or activated at predetermined intervals or gradually over a period of time.
References in periodicals archive ?
25, 2015 /PRNewswire/ -- The controlled-release fertilizers market is growing due to its ability to increase the efficiency of crop production.
The report"Controlled-Release Fertilizers Market by Type (Condensation Products of Urea, Coated & Encapsulated Fertilizers, and N-stabilizers), Crop Type (Cereals & Oilseeds, Turf & Ornamentals, and Fruits & Vegetables), & by Region - Global Trends and Forecast to 2020" published by MarketsandMarkets, The Controlled-Release Fertilizers Market was valued at USD 2,178.
According to the report, the global market for controlled-release barrier materials will approach $1 billion by 2015, increasing from nearly $600 million in 2010, a compound annual growth rate (CAGR) of 10.
Gliclazide-Controlled Release Tablets is a modified controlled-release antidiabetic drug to treat type 2 diabetes.
marketer of long-acting pain medications, including OxyContin(R) (oxycodone HCl controlled-release) Tablets and MS Contin(R) (morphine sulfate controlled-release) Tablets, and with its extensive patent portfolio related to controlled-release tramadol, Purdue is the ideal partner for our product in the United States," said Dr.
Clearly, he says, Kim's controlled-release drug implant "is the farthest along of the self-regulating.
Controlled-release fertilizers are gaining importance due to the global awareness of sustainable agriculture which demands step-by-step reduction in the cost of farming and meets environmental safety standards.
Controlled-release oral dosage forms can often yield a decrease in the dosing frequency and a reduction in peak plasma concentrations.
com/research/a4ffa3/emerging_opportuni) has announced the addition of the "Emerging Opportunities in Controlled-Release Generic Drugs" report to their offering.
14, 2014 /PRNewswire/ -- Controlled-release or slow-release fertilizers (CRFs or SRFs) are also known as enhanced efficiency fertilizers.
Bernard Berk, Elite's Chairman and Chief Executive Officer will provide an update on the developments of the Company's two lead opioid products: ELI-216, the Company's abuse-deterrent oxycodone hydrochloride product using ART[TM], and ELI-154, its once-daily oxycodone hydrochloride product along with its pipeline of other oral controlled-release products addressing niche markets.

Full browser ?